Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction

Circulation

Volumn 112, Issue 10, 2005, Pages 1494-1499

  Hong, Zhigang ^a   Smith, Andrew J ^a   Archer, Stephen L ^b   Wu, Xi Chen ^b   Nelson, Daniel P ^a   Peterson, Douglas ^a   Johnson, Gerhard ^a   Weir, E Kenneth ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drugs; Hypertension, pulmonary; Ion channels; Muscle, smooth; Vasoconstriction

Indexed keywords

ANOREXIGENIC AGENT; PERGOLIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOID LIKE HEART VALVE DISEASE; CARDIOTOXICITY; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; HUMAN; HUMAN CELL; HYPOXIA; LUNG ARTERY; LUNG ARTERY PRESSURE; LUNG VASOCONSTRICTION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; CALCIUM; CHO CELLS; CRICETINAE; DOPAMINE AGONISTS; HUMANS; KV1.5 POTASSIUM CHANNEL; MALE; MUSCLE, SMOOTH, VASCULAR; PATCH-CLAMP TECHNIQUES; PERFUSION; PERGOLIDE; POTASSIUM CHANNEL BLOCKERS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; TRANSFECTION; VASOCONSTRICTION;

EID: 24744440793     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.556704     Document Type: Article

References (28)

1. 2 receptors. Life Sci. 1991;49:925-930.
2. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Fache JC, Burkhard PR, Lang AE. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656-662.
3. Mondal BK, Suri S. Pergolide-induced retroperitoneal fibrosis. Int J Clin Pract. 2000;54:403.
4. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
5. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B, for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
6. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996;94: 2216-2220.
7. Reeve HL, Nelson DP, Archer SL, Weir EK. Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology. Am J Physiol. 1999;276:L213-L219.
8. Olschewski A, Hong Z, Peterson DA, Nelson DP, Porter VA, Weir EK. Opposite effects of redox status on membrane potential, cytosolic calcium and tone in pulmonary arteries and ductus arteriosus. Am J Physiol. 2004;286:L15-L22.
9. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation. 2003;107: 2037-2044.
10. Rahimtoola SH. Drug-related valvular heart disease: here we go again: will we do better this time? Mayo Clin Proc. 2002;77:1275-1277.
11. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002;77:1280-1286.
12. Baseman DG, O'suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004;63:301-304.
13. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 2003;61:859-861.
14. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179-1183.
15. Teramae CY, Connolly HM, Grogan M, Miller FA Jr. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc. 2000;75:456-461.
16. Rubin A, Lemberger L, Dhahir P. Physiologic disposition of pergolide. Clin Pharmacol Ther. 1981;30:258-265.
17. Physicians' Desk Reference 2005. Montvale, NJ: Thomson PDR; 2005:3276.
18. 2+, independent of membrane potential. Am J Physiol. 1999;277:L662-L666.
19. Hong Z, Olschewski A, Reeve HL, Nelson DP, Hong F, Weir EK. Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol. 2004;286:L531-L538.
20. Hurst RS, Higdon NR, Lawson JA, Clark MA, Rutherford-Root KL, McDonald WG, Haas JV, McGrath JP, Meglasson MD. Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol. 2003;482:31-37.
21. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol. 2003; 63:1223-1229.
22. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836-2841.
23. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57:75-81.
24. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8:1129-1135.
25. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA III, Loyd JE. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001;345:319-324.
26. Remillard CV, Fantozzi I, Platoshyn O, Wong A, Petrauskene O, Zhang S, Yuan JX. Bone morphogenetic protein-2 enhances Kv channel expression and function in human pulmonary artery smooth muscle cells. Proc Am Thor Soc. 2005;2:A723. Abstract.
27. + channels: an essential pathway in programmed cell death. Am J Physiol. 2004;286:L49-L67.
28. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, Juhaszova M, Seiden JE, Rubin LJ, Yuan JX. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol. 2000;279:C1540-C1549.